NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai UniXell Biotechnology

Shanghai UniXell Biotechnology

Private
ShanghaiHealthcare & Life Scienceshttps://unixell.com/

Last Round

Series A

Apr 18, 2025

Total Funding Raised

$71.38M

Company Overview

Shanghai UniXell Biotechnology is a biotechnology company that develops human pluripotent stem cell (hPSC) based cell therapies for neurodegenerative and rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyregenerative medicineiPSC technologyParkinson's disease treatmentneurodegenerative diseasesautologous cell therapyallogeneic cell therapyinduced pluripotent stem cellsGMP manufacturingclinical-stage biotechnologyepilepsy treatmentstem cell differentiationgene editing platformhuman pluripotent stem cellhPSC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai UniXell Biotechnology Comps

Public and private peers based on sector, stage, and business model.

Shanghai UniXell Biotechnology comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Shanghai UniXell Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 18, 2025
Series AJul 12, 2024
Series AApr 4, 2024
Pre SeedMar 14, 2022
AngelAug 25, 2021

Shanghai UniXell Biotechnology Investors

Notable investors and investment history

Shanghai UniXell Biotechnology investors
InvestorRounds
Hillhouse InvestmentPre Seed
Guokejiahe FundSeries A
TF CapitalPre Seed
CAS Venture CapitalSeries A
Jiangsu Ruihua Investment Holding GroupPre Seed
Kunlun CapitalSeries A
Tasly CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2025

    $19.18M round with participation from Guokejiahe Fund and Kunlun Capital.

  • Jul 12, 2024

    $1.38M round led by The Chinese Academy of Sciences Venture Capital Management

Shanghai UniXell Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai UniXell Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai UniXell Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2021
Last FundingApr 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.